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Abstract
Background: The resolution of inflammatory responses in the lung has not been described in
detail and the role of specific cytokines influencing the resolution process is largely unknown.
Methods: The present study was designed to describe the resolution of inflammation from 3 h
through 90 d following an acute injury by a single intratracheal instillation of F344/N rats with LPS.
We documented the inflammatory cell types and cytokines found in the bronchoalveolar lavage
fluid (BALF), and epithelial changes in the axial airway and investigated whether IL-18 may play a
role in the resolution process by reducing its levels with anti-IL-18 antibodies.
Results: Three major stages of inflammation and resolution were observed in the BALF during the
resolution. The first stage was characterized by PMNs that increased over 3 h to 1 d and decreased
to background levels by d 6–8. The second stage of inflammation was characterized by macrophage
influx reaching maximum numbers at d 6 and decreasing to background levels by d 40. A third stage
of inflammation was observed for lymphocytes which were elevated over d 3–6. Interestingly, IL-
18 and IL-9 levels in the BALF showed a cyclic pattern with peak levels at d 4, 8, and 16 while
decreasing to background levels at d 1–2, 6, and 12. Depletion of IL-18 caused decreased PMN
numbers at d 2, but no changes in inflammatory cell number or type at later time points.
Conclusion: These data suggest that IL-18 plays a role in enhancing the LPS-induced neutrophilic
inflammation of the lung, but does not affect the resolution of inflammation.
Background
Processes involved in the initial generation of inflamma-
tion, i.e, infiltration of the lung air spaces by inflamma-
tory cells and the associated changes in the airway
epithelium, have been studied in great detail. However,
only recent studies have focused on the resolution of
inflammation that is generally characterized by a reduc-
tion in the number of inflammatory cells and the associ-
ated healing process of the airway epithelium. These
studies have shown that the resolution of inflammation is
not passive but an active and coordinated process with
certain factors enhancing the resolution [1]. Understand-
ing the events associated with normal resolution of acute
airway inflammation could provide a basis for treatment
and prevention of inflammatory diseases. Although sev-
eral studies have focused on lipid mediators involved in
the resolution of polymorphonuclear (PMN) cell influx
and inflammation from various inflammatory insults
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[2,3], studies characterizing the resolution as a whole and
cytokine patterns over longer periods after LPS-induced
inflammation have not been reported.
Intratracheal instillation of LPS in the rat is designed to
mimic the inflammatory response in patients with gram-
negative bacterial infections. It is possible that aberrant
repair processes are responsible for sustained pulmonary
inflammation in the lung and airway remodeling
observed in chronic diseases such as asthma and chronic
bronchitis. Understanding the resolution process and fac-
tors that may be responsible for sustained inflammation
or enhanced resolution are crucial to develop meaningful
intervention strategies.
We have previously described the resolution of LPS-
induced goblet cell metaplasia (GCM) in F344/N rats
[4,5]. In order to identify possible mediators that affect
the resolution of inflammation in the lung and thereby
the factors that may affect the resolution of GCM we
quantified inflammatory cells, major cytokines, and
growth factors in the bronchoalveolar lavage fluid (BALF),
and determined changes in the airway epithelium over a
period of 90 d post-LPS instillation. Neutrophils [6], mac-
rophages [7], and lymphocytes [8] have been shown to
affect mucin expression and GCM directly or indirectly by
modifying the presence of inflammatory mediators or
affecting the resolution of inflammation. Therefore, we
determined their numbers and the levels of inflammatory
mediators during the course of resolution from an acute
inflammatory response following LPS instillation. A 90-d
study was selected to allow for the complete resolution of
LPS-induced inflammatory cell influx.
This study showed that the resolution process is character-
ized by three stages of inflammation and demonstrated
how the resolution of epithelial cell hyperplasia correlates
with the resolution of inflammatory cells. IL-18 is a proin-
flammatory cytokine that can induce the p 38 MAP kinase
pathway [9] and IFNγ-production in lymphocytes [10,11]
and its levels showed a cyclic pattern over days 4–16.
Despite its presence in the later stages of inflammation,
reduction of IL-18 levels decreased neutrophilic inflam-
mation at 2 d but did not affect infiltration of the lung by
other inflammatory cell types or the resolution process
following LPS instillation.
Materials and methods
Animals
Male pathogen-free F344/N rats (NCI-Frederick Cancer
Research, Frederick, MD) were housed in pairs and pro-
vided food and water ad libitum. The rats were provided a
12:12-h light/dark cycle and an environment of 22°C and
30–40% humidity. Rats were randomly assigned to each
experimental group, and were 9 wk of age at the beginning
of this study. All animal experiments were carried out at
Lovelace Respiratory Research Institute, a facility
approved by the Association for the Assessment and
Accreditation for Laboratory Care International.
LPS-instillation and bronchoalveolar lavage
Rats were briefly anesthetized with 5% halothane in oxy-
gen and nitrous oxide and instilled intratracheally (i.t.)
with 1000 μg of LPS (Pseudomonas aeruginosa serotype 10,
lot 31K4122, 3,000,000 endotoxin units [EU]/mg, Sigma-
Aldrich, St. Louis, MO) in 0.5 ml of 0.9% pyrogen-free
saline solution. Control rats were instilled with 0.5 ml of
0.9% pyrogen-free saline. Rats were sacrificed 3 h and d 1,
2, 3, 4, 6, 8, 12, 16, 40, and 90 post instillation with an
injection of sodium pentobarbital and exsanguinated
through the renal artery. Additional control groups of
uninstilled naïve rats were sacrificed at the beginning and
end of the study. The lungs were removed, lavaged and
fixed as described previously. [12]
Analysis of BALF
The total number of cells from the BALF were counted and
the numbers of specific cell types were calculated as
described previously [13]. The rat LINCO plex kit (LINCO
research, Inc., St Charles, MO) was used according to
package directions to determine levels of rat IL-1α, IL-1β,
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-18, IFNγ, TNF-α, mac-
rophage chemoattractant protein-1 (MCP-1), granulo-
cyte-macrophage colony-stimulating factor (GM-CSF),
and Gro/KC (a chemoattractive factor). Levels were meas-
ured on a Luminex 100 system and data were analyzed
using StatLIA software from Brendan Scientific (Grosse
Point Farms, MI). Vascular endothelial growth factor
(VEGF), insulin-like growth factor (IGF)-1, and IL-13 were
measured with the R&D Systems, Inc. VEGF RatDuoSet
(Minneapolis, MN), Octeia rat/mouse IGF-1 assay
(Immunodiagnostic Systems, Fountain Hills, AZ), and the
Biosource International Rat IL-13 ELISA (Camarillo, CA),
respectively, according to manufacturer's directions. For
graphical representation, values below detection limits
were set to 0 pg/ml.
Because rat IL-9 was not commercially available, IL-9 lev-
els in saline-and LPS-instilled rats were compared to unin-
stilled controls using an anti-human IL-9 antibody. BALF
samples were plated in triplicate in wells of polyvinyl
chloride, high-protein-binding, 96-well Costar plates
(Corning-Incorporated Life Sciences, Acton, MA) and
allowed to dry at 37°C overnight. The wells were blocked
with PBS containing 1% normal goat serum for 45 min.
Rabbit anti-human IL-9 antibody (Chemicon Interna-
tional, Inc., Temecula, CA) was diluted to 0.5 μg/ml in
blocking solution, and the plates were incubated at 37°C
for 2 h, then washed with PBS. A Vector Laboratories ABC
kit (Burlington, Ontario) was used to detect the boundRespiratory Research 2007, 8:24 http://respiratory-research.com/content/8/1/24
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anti-IL-9 antibody, with the secondary antibody at a dilu-
tion of 1:200 in blocking solution and the ABC reagents
prepared according to package directions. The horseradish
peroxidase substrate tetramethylbenzidine was used to
visualize the bound antiIL-9 antibody and was detected
with a VERSAmax plate reader (Molecular Devices Corpo-
ration, Sunnyvale, CA) at 450 nm with a reduction at 650
nm.
LPS quantification
The amount of LPS recovered in the BALF was assayed in
duplicate using the Cambrex LAL Limulus Amoebocyte
Assay (Walkersville, MD) according to package directions.
Values are expressed in international endotoxin units
(EU).
Histology
The intrapulmonary airways of the left lung lobe from
each animal were microdissected according to a previ-
ously described procedure [6]. Lung slices were embedded
in paraffin, and 5-μm-thick sections were prepared for
analysis of airway epithelia. Both the proximal and distal
axial airway sections at generations 5 and 11, respectively,
were analyzed for each of our data sets.
Histochemical staining and analysis
Tissue sections were stained with Alcian blue, hemotoxy-
lin and eosin (AB/H & E) as described [14]. Quantifica-
tion of the total numbers of mucin-storing and non-
mucin-storing epithelial cells was performed by a person
unaware of slide identity using the National Institute of
Health's image analysis system (Bethesda, MD) by count-
ing the number of nuclei and dividing by the length of the
basal lamina.
IL-18 neutralization
Rats were anesthetized on day 0 as described above and
i.t. instilled with 30 μg rat anti-mouse IL-18 (MBL Medical
and Biological Laboratories, Nagoya, Japan) or with 30 μg
rat IgG1 isotype control (R&D Systems) in 300 μl saline
and returned to their cages. After 1 h, all rats were re-anes-
thetized and instilled with 1000 μg LPS. Rats received i.p.
injections of 10 μg anti-IL-18 or IgG1 on days 1, 3, 5, and
7, and were sacrificed on days 2, 4, and 8, post LPS instil-
lation as described above.
Statistical methods
Numerical data were expressed as the mean group value ±
SEM. Data were analyzed using the Statistical Analysis
Software (SAS) from the SAS Institute, Inc. (Cary, NC).
Results grouped by time point and dose were analyzed
using a two-way analysis of variance (ANOVA); values
that were considered significantly different from each
other by ANOVA were further analyzed using a post-hoc
Tukey's t test. Data having only two groups were analyzed
using a Student's t test. The criterion for significant differ-
ences was P < 0.05 for all studies.
Results
Inflammatory cells in the BALF
The resolution of inflammatory cell influx into the lung
was determined over a 90 d period post LPS instillation.
The total inflammatory cells in the BALF reached maxi-
mum levels at d 1 and 6 post LPS instillation and returned
to background levels by d 40 post instillation of LPS (Fig.
1A). The number of PMNs in the BALF was statistically
increased compared to saline-instilled controls at 3 h, and
reached maximum numbers at d 1, before dropping to
control levels by d 8 post instillation (Fig. 1B). The
number of macrophages in the BALF began to increase at
1 d, reached maximum levels at 6 d post instillation of
LPS, and decreased over 40 d when they were no longer
statistically significant from saline-instilled controls. (Fig.
1C). Lymphocyte numbers, although 10-fold lower than
the numbers for PMNs and macrophages, reached maxi-
mum levels at d 3 through 6 and decreased to levels
observed in saline-instilled controls at 40 d (Fig. 1D).
Eosinophils were not present in the BALF.
LPS and inflammatory factors in BALF
The amount of LPS recovered in the BALF was highest at 3
h post-instillation and decreased to levels found in saline
instilled controls by d 4 (Fig. 2A). We determined the lev-
els of chemokines and cytokines in the BALF that have
been reported to be important in recruiting and activating
inflammatory cells to the airways and those that play a
role in mucin synthesis and storage.
IL-1α (Fig. 2A) was highest at 3 h post-instillation of 1000
μg LPS, decreased to background levels by d 4, and
remained low through 90 d. Saline-instilled controls had
low levels of IL-1α and β at 3 h and became undetectable
by d 4. Similar results were seen with IL-6 (Fig 2A). MCP-
1 and IL-1β (Fig 2A) were highest at d 1 and returned to
background levels by d 2 and 6 post instillation, respec-
tively. GRO-KC and TNF-α (Fig. 2A), were both highest at
3 h post instillation, but LPS-instilled rats were not statis-
tically different from saline-instilled controls. While both
cytokines were reduced at day 1, the resolution of these
cytokines was significantly delayed in LPS-instilled rats
compared to saline-instilled controls. IL-2, IL-4, IL-5, IL-
10, IL-12, IL-13, IFNγ, IGF-1, and GM-CSF were below the
detection levels of our assays.
VEGF levels (Fig. 2B) were decreased over 3 d, increased
over 4–6 d and were again significantly decreased com-
pared to saline-instilled controls at d 16. However, VEGF
increased again at 40 and 90 d to levels observed in rats at
0 d.Respiratory Research 2007, 8:24 http://respiratory-research.com/content/8/1/24
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Three stages of inflammatory cell influx were identified in the  BALF, characterized by PMNs, macrophages, and lym- phocytes Figure 1
Three stages of inflammatory cell influx were identified in the 
BALF, characterized by PMNs, macrophages, and lym-
phocytes. White blood cells on cytospins were stained with 
Wright Giemsa and cell counts were performed. A: Total 
leukocytes; B Neutrophils; C:Macrophages; and D: Lym-
phocytes. Bars represent group mean values ± SEM (n = 5 
rats per experimental group), * = statistically different from 
saline-instilled controls (P < 0.05).
Interestingly, IL-9 and IL-18 showed a cyclical pattern dur-
ing the resolution of inflammation. In LPS-instilled rats,
both cytokines were at levels similar to saline-instilled rats
at d 2, 6, 12, 40, and 90, but were significantly elevated at
d 4, 8, and 16 post LPS instillation. IL-18 levels were high
in non-instilled rats and showed an overall gradual
decrease over 40 and 90 d (Fig. 2C). BALF from non-
instilled rats the same age as our instilled rats at the 40
and 90 d time points showed that IL-18 decreases with age
and was not statistically different from either rats instilled
with saline or LPS at that time point (data not shown).
Goblet cells and total epithelial cell number
We have previously shown that LPS instillation results in
epithelial cell hyperplasia that is manifested as GCM [15].
To determine how the resolution of inflammation corre-
lates with the resolution of GCM, we quantified mucus
storing and non-mucus storing cells per millimeter basal
lamina (BL) over 90 d post instillation. In this animal
model GCM does not occur until d 2 post instillation
[15]. Therefore, we excluded 3 h and 1 d from our histo-
logical quantifications. Morphometric results were similar
in both proximal (airway generation 5) and distal (airway
generation 11) airways.
Non-mucus cells per millimeter basal lamina (BL)
remained statistically unchanged with approximately 90–
120 cells/mmBL throughout the 90 d (Fig. 3). Rats
instilled with 1000 μg LPS showed a significant increased
number of total epithelial cells per mmBL compared to
saline-instilled controls due to increase in mucous cells at
d 3, 4, and 6. GCM declined significantly from 4 to 12 d,
and remained at levels observed in saline-instilled con-
trols through the 40-d time point.
IL-I8 depletion
The cyclic pattern of IL-18 levels showed decreases at 6,
12, and 40 d post LPS instillation, when the numbers of
PMNs, macrophages, and hyperplastic epithelial cells had
declined to background levels. Therefore, we hypothe-
sized that this cytokine may have a role in enhancing the
resolution of inflammation and GCM. Studies have sug-
gested that IL-18 may be associated with acute inflamma-
tion in the lung [16] or liver [17]. To test whether IL-18
directly affects the resolution of inflammation in our
model, we depleted IL-18 in rats instilled with LPS and
analyzed the inflammatory response at d 2, 4, and 8.
Injection with IL-18 antibodies reduced IL-18 levels in the
BALF compared to IgG1-treated controls at 4 d post LPS
instillation (Fig. 4). Interestingly, IL-18 levels in the BALF
were unaffected at d 2 and 8. MCP-1, IL-1α, IL-1β and
GRO-KC remained unchanged in treated animals com-
pared to controls at all three time points (data not
shown). Rats treated with anti-IL-18 and IgG1 did notRespiratory Research 2007, 8:24 http://respiratory-research.com/content/8/1/24
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Inflammatory mediators detected in the BALF Figure 2
Inflammatory mediators detected in the BALF. A The amount of LPS recovered in the bronchoalveolar lavages was 
measured using the Limulus Amoebocyte Assay and expressed in international endotoxin units (EU/ml). BALF from rats 
instilled with saline or 1000 μg LPS were analyzed for cytokines and growth factors by multiplex ELISA and levels of IL-1α, IL-
1β, IL-6, TNF-α, GRO-KC, and MCP-1 over 90 d post instillation are shown. B. VEGF was only increased at 8 d post- instilla-
tion of 1000 μg LPS compared to saline-instilled rats. C. IL-18 and IL-9 exhibit a cyclic pattern of expression over 90 d post 
instillation. Bars represent group mean values ± SEM (n = 5 rats per experimental group) * = statistically different from saline-
instilled controls (P < 0.05).Respiratory Research 2007, 8:24 http://respiratory-research.com/content/8/1/24
Page 6 of 12
(page number not for citation purposes)
exhibit differences in total numbers of leukocytes in the
BALF (Fig. 5A) but showed a decrease in PMNs in the
BALF at d 2 post LPS instillation (Fig 5B). The number of
macrophages and lymphocytes remained unchanged
compared to controls (Fig. 5C, D). LPS recovered by bron-
choalveolar lavage was also unchanged in IL-18-depleted
rats compared to controls (data not shown). Goblet cell,
non-mucous cell and total epithelial cell numbers were
not significantly increased in rats treated with anti-IL-18
compared to rats treated with control IgG1 at d 2, 4 or 8
(Fig. 6). However, both antibody treatments significantly
increased total numbers of goblet cells at d 2 post instilla-
tion compared to rats instilled only with LPS.
Discussion
The present study shows that following LPS-instillation,
resolution of inflammatory cells and cytokines in the
BALF is characterized by three different stages - influx of
PMNs, macrophages, and lymphocytes into the lung air-
spaces. In addition, we show that IL-18 is not involved
with the resolution process, but enhances influx of PMNs
immediately after LPS instillation.
LPS-induced injury causes epithelial cells and macro-
phages [18,19] to produce C-X-C chemokines, such as
GRO/KC (one of the murine IL-8 homologues) that
attract neutrophils to the airspaces [20]. Therefore, neu-
trophils are the first cells at the scene following LPS instil-
lation [3,21,22] and may be associated with the clearance
of LPS [23] as shown by our finding that LPS in the BALF
was reduced to background levels within 2 days. Removal
of the initial stimulus, i.e. LPS, is critical, because persist-
ence of offending agent could lead to chronic and ongo-
ing inflammation.
The appearance of IL-1β, IL-1α, IL-6, and TNF-α, and
MCP-1 in the BALF correlates with the first stage. The C-C
chemokines such as MIP-1 are predominantly chemoat-
tractants for monocytes [24] and the cytokines including
TNFα, IL-1α and β and IL-6 can activate macrophages
[25]. Because neutrophils are short-lived and undergo
apoptosis within hours of entering the airspaces [26,27]
activated macrophages must be present at increased num-
bers to enhance the capacity to clear apoptotic neutrophils
by phagocytosis [28,29]. Therefore, the appearance of
Total cell and goblet cell numbers reach maximum levels 4 d post instillation of 1000 μg LPS Figure 3
Total cell and goblet cell numbers reach maximum levels 4 d post instillation of 1000 μg LPS. Numbers of non-mucin storing 
epithelial cells/mmBL remain unchanged throughout the 90 d and are shown as white bars. Goblet cells per mmBL are shown as 
filled bars. Values given are ± SEM, (n = 5 rats per experimental group), * = statistically different from saline-instilled controls (P 
< 0.05).Respiratory Research 2007, 8:24 http://respiratory-research.com/content/8/1/24
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macrophages in the BALF defines the second stage. The
clearance of inflammatory cells is also among the first
steps in resolving the inflammatory responses [30,31].
Our observation that VEGF levels were decreased over 72
h post LPS instillation are consistent with other reports
[32]. VEGF production peaks several days after injury in
various systems [33] and is important in the resolution of
inflammation in some tissues, because this process is
characterized by enhanced angiogenesis [34]. The early
production of angiogenic factors, such as TNFα followed
by release of VEGF is believed to allow the formation of
blood vessels that provide nutrients to tissues and allow
trafficking of immune cells. Furthermore, recent studies
suggest that dendritic cells when matured in the presence
of anti-inflammatory molecules secrete VEGF and pro-
mote angiogenesis [35].
We found maximum numbers of macrophages at 6 d post
LPS instillation, the same time point when increases in
VEGF levels were detected in LPS- compared to saline-
instilled rats. VEGF can be produced by various cell types
[36,37], and our findings indicate that macrophages may
be the main source for VEGF in the BALF at d 6 and 8 after
LPS instillation. However, airway epithelial cells can also
express VEGF when treated with IL-1β, TNFα, or neu-
trophil elastase [37]. Therefore, increase of IL-1β, TNFα,
and other mediators at early time points following LPS-
instillation may have initiated production of VEGF at d 6–
8 post instillation.
Reduction of IL-18 levels in the BALF of rats instilled and  injected with anti IL-18 or control IgG1, then instilled with  LPS and sacrificed 2, 4 and 8 d post instillation Figure 4
Reduction of IL-18 levels in the BALF of rats instilled and 
injected with anti IL-18 or control IgG1, then instilled with 
LPS and sacrificed 2, 4 and 8 d post instillation. BALF was 
obtained from IL-18-depleted and control rats as described 
above and IL-18 was determined using Luminex 100 technol-
ogy. n = 3–6 rats per group. * = statistically different from 
controls treated with IgG1 (P < 0.05).
Inflammatory cell influx in BALF of rats instilled and injected  with IL-18 neutralizing antibody and then instilled with LPS Figure 5
Inflammatory cell influx in BALF of rats instilled and injected 
with IL-18 neutralizing antibody and then instilled with LPS. 
Their lungs were lavaged and cytospin preparations were 
stained with Wright/Giemsa. The number of (A) Total leuko-
cytes (B) PMNs; * = statistically different from controls 
treated with IgG1 (P < 0.05). (C) Macrophages;(D) Lym-
phocytes are shown. n = 3–6 rats per group.Respiratory Research 2007, 8:24 http://respiratory-research.com/content/8/1/24
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The number of lymphocytes reaches maximum at 3–6 d
characterizing the third stage of inflammation and is still
10-fold lower than the number of PMNs and macro-
phages when they reach peak levels. T lymphocytes may
be the primary source of IL-9 [38] and IL-18 [39] while IL-
9 can also be produced by neutrophils in the lung [38]. IL-
9 and IL-18 levels in the BALF decreased as non-instilled,
saline-instilled or LPS-instilled rats aged over 90 d. How-
ever, in LPS-instilled rats, their levels decreased initially
then increased in a cyclic manner at d 4, 8, and 16. These
cyclic increases and decreases in IL-9 and IL-18 spanned
all 3 stages of inflammation. To our knowledge, such
cyclic pattern has not been reported during resolution of
acute inflammation.
We tested the lavage fluid for the known anti-inflamma-
tory cytokine, IL-10, assuming that this cytokine may be
crucial in the resolution process. However, this cytokine
was below detection levels (1 pg/ml). The other cytokine
that is associated with resolution of inflammation is TGF-
β. While several studies that have exposed rodents to LPS
and reported that they did not detect increased TGFβ lev-
els in the lung tissues [40,41] apoptotic cell recognition by
activated macrophages and clearance induces TGF-β1
secretion resulting in accelerated resolution of inflamma-
tion [42]. Whether active or latent forms of TGF-β1
enhance resolution LPS-induced inflammation will be
studied in the future.
The onset of GCM correlates with the decline of PMN
numbers as was shown in previous studies [12,6,15], and
is maintained through d 6 when macrophage numbers are
highest. We also observed that macrophage and PMN
numbers were equal and lymphocyte numbers were max-
imum by d 4 when GCM is highest, suggesting that a com-
bination of factors derived from these cell types, may be
contributing to epithelial cell hyperplasia and increased
mucin synthesis and storage resulting in GCM. It is estab-
lished that IL-6, produced by both macrophages and neu-
trophils [21], induces mucin synthesis [43]. IL-1β is
produced by both PMNs [21] and lymphocytes [22] and
can activate the MUC5AC promoter [44] in primary air-
way epithelial cells. Furthermore, neutrophil elastase pro-
longs the half-life of MUC5AC mRNA [45] and also leads
to increased mucin expression through the generation of
reactive oxygen species [46]. Increased IL-9 levels at 4 and
8 d correlate with increased GCM and are consistent with
studies showing that IL-9 is necessary for the development
of GCM [16,47,48]. GCM following acute injury or
inflammatory responses results from differentiation of
pre-existing epithelial cells into mucous cells and differen-
tiation of proliferating cells to mucous cells [15,49].
Therefore, the inflammatory mediators may cause epithe-
lial cell proliferation and directly induce mucin synthesis
in pre-existing and proliferating epithelial cells in vivo.
When the number of mucous cells/mm basal lamina is
subtracted from the total epithelial cell number at each
time point, no major changes were observed during the
resolution, indicating that the increase in total epithelial
cell numbers is entirely composed of hyperplastic mucous
cells. The reduction in the number of mucus-producing
cells coincides with the total removal of PMNs and is asso-
ciated with the decline of macrophage and lymphocyte
numbers in the lavage fluid. The resolution of GCM
involves various mechanisms. First, some of the mucous
cells appear to transdifferentiate into non-mucus cells.
This change must involve reducing mucus synthesis and
possibly differentiating into ciliated [50] or serous cells
(personal unpublished observation). This process of
transdifferentiation could be due to the decline in
cytokines and other inflammatory mediators responsible
for mucin gene expression and the presence of a combina-
tion of inflammatory mediators stimulating the differen-
tiation of these cells into another epithelial cell
phenotype. Second, the resolution of GCM involves the
reduction of approximately 30% of airway epithelial cells
being removed from the epithelium. Because all of these
cells represent mucus-producing cells, this mechanism
may account for the reduction of at least 1/3 of mucus
production. Our previous studies have shown that Bcl-2,
an anti-apoptotic protein, is expressed in metaplastic
mucous cells of LPS-instilled rats [4,15]. This resolution is
at least in part orchestrated by Bcl-2 being downregulated
allowing the pro-apoptotic members to elicit cell death
and reduce the number of hyperplastic epithelial cells
[5,51]. Whether the decline in specific cytokine levels
causes downregulation of Bcl-2 expression and thereby
The number of total and metaplastic goblet cells in the air- ways of rats injected with IL-18 neutralizing antibody or IgG1  as control and then instilled with LPS Figure 6
The number of total and metaplastic goblet cells in the air-
ways of rats injected with IL-18 neutralizing antibody or IgG1 
as control and then instilled with LPS. Non mucous cells are 
shown as white bars and goblet cells per mmBL are shown as 
filled bars. n = 3–6 rats per groupRespiratory Research 2007, 8:24 http://respiratory-research.com/content/8/1/24
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the cell death of hyperplastic epithelial cells is being inves-
tigated.
IL-18 in the BALF showed a cyclic pattern decreasing to
background levels on d 6, when PMNs and the early
cytokines had declined, then on d 12, when GCM was
resolved, and lastly on d 40, when the macrophage and
lymphocyte numbers had declined to background levels
(Fig. 7). Because the role of IL-18 is largely unknown and
we observed an unusual cyclic pattern of this cytokine
during the resolution process we hypothesized that this
cytokine may have importance in regulating resolution.
Rats instilled with IgG1 showed increased GCM already at
2 d post LPS instillation while GCM was not observed in
rats instilled with LPS only, suggesting that the antibody
itself enhanced LPS-induced inflammation as is mani-
fested by the doubling in the number of PMNs in LPS-
instilled rats treated with IgG1 compared to those instilled
with LPS only. Treating a group of rats with a 60-μg instil-
lation followed by LPS instillation and 20-μg injections of
anti-IL-18 or IgG1 as control caused such an increase in
lung inflammation that the axial airway epithelium was
completely denuded at 4 d post instillation (data not
shown). Therefore, we determined that a smaller dose of
antibody that maintained airway structure was more
appropriate for our study. Furthermore, the total cell
numbers of inflammatory cells at days 2 and 4 d was
lower in LPS instilled rats compared to those instilled with
LPS and treated with IgG1  and anti-IL-18 antibodies.
While the numbers of macrophages and lymphocytes
remained similar, increased influx of PMNs in anti-IgG1-
treated rats likely caused GCM to increase earlier than in
rats instilled with LPS only. Consistent with these find-
ings, previous studies have documented that GCM can be
reduced by depleting PMNs [6,12]. The lack of resolution
of GCM at d 8 post LPS instillation in both the IgG1- and
anti-IL-18-treated groups may be due to sustained changes
within the airway epithelia because of elevated levels of
cytokines.
The time points 2, 4, and 8 d post instillation were chosen
for studying the effect of IL-18 depletion because major
changes associated with resolution of inflammation were
observed in the lungs of LPS-instilled rats at those time
points: At d 2, PMN numbers in the BALF were reduced to
50% of their maximum; at d 4, GCM had reached maxi-
mum and PMN and macrophage numbers detected in the
BALF were equal; at d 8, macrophage numbers were
reduced to 50% of their maximum and GCM was reduced
compared to maximum levels by d 8.
Our initial treatment with anti-IL-18 by i.t. instillation
only did not reduce IL-18 levels in the BALF; therefore, we
administered anti-IL-18 i.p. in addition to the i.t. instilla-
tion. Interestingly, IgG1 itself reduced LPS-induced IL-18
levels by one half, and this decrease was consistent
throughout the time course studied. While anti-IL-18 was
administered before and after LPS instillation, we found
significant reduction in IL-18 levels only on d 4; why IL-
18 levels were not reduced on d 2 post LPS instillation
may be due to anti-IL-18 levels not having reached maxi-
mum levels at the early time point. Furthermore, compen-
satory mechanisms may have overruled the anti-IL-8 effect
at d 8, reducing the difference to non-significant levels.
It is possible that the anti-IL18 IgG could have in-specific
effects and neutralize other inflammatory factors. How-
ever, because the detected levels for MCP-1, IL-1α, and IL-
1β were unchanged in anti-IL-18-treated rats compared to
controls, we do not believe that the presence of anti-IL-18
antibody in the lavage could have affected the detection of
cytokines. Reduction of IL-18 in the BALF and serum of
rats treated with anti-IL-18 antibodies caused a significant
decrease in pro-inflammatory serum cytokines such as IL-
12, IL-6, and IFNγ at d 4 post LPS instillation compared to
controls (data not shown). These findings suggest a role
for IL-18 in the balance of cytokines in the blood during
lung inflammation and resolution.
IL-18 depletion of LPS-instilled rats decreased the number
of PMNs in the BALF at an early time point (2 d) com-
pared to the IgG1-treated rats. Our findings are consistent
with a short-term study of acute lung inflammation show-
ing that IL-18 enhances PMN migration into the lung
[16]. Studies of cystic fibrosis patients positive for Pseu-
domonas aeruginosa showed that BALF and leukocytes
obtained from the BALF exhibit decreased levels of IL-18
compared to healthy control patients [52,53]. However,
because IL-18 levels in CF tissues are higher than in con-
trol tissues, it is believed that the IL-18 detection in CF lav-
age is compromised by an unknown factor masking its
detection [53]. In another study, pretreatment of allergen-
sensitized mice with anti-IL-18 followed by an allergen
challenge decreased PMN influx initially, but did not
affect tissue inflammation, numbers of PMNs, or GCM at
later time points. The lack of increased cytokine levels or
leukocyte numbers in the BALF despite increased PMN
numbers in anti-IL-18-treated rats suggests that there may
be compensatory mechanisms maintaining the cytokine
response to LPS.
The observation that IL-18 levels decreased immediately
after LPS instillation when PMN influx was highest
appears somewhat contradictory since treatment with
anti-IL-18 antibodies reduced PMN numbers in the BALF
at d 2 compared to IgG1 treatment. However, these find-
ings suggest that the elevated amount of IL-18 present in
the lung before LPS instillation may be crucial to the PMN
influx and the decline of IL-18 from 3 h through d 2 in theRespiratory Research 2007, 8:24 http://respiratory-research.com/content/8/1/24
Page 10 of 12
(page number not for citation purposes)
LPS-challenged lung may prevent excessive neutrophilic
inflammation and airway damage.
In summary, the present study shows that LPS-induced
airway inflammation follows classic stages of resolution
for PMNs, macrophages, lymphocytes and certain
cytokines, but includes patterns of inflammation for IL-9
and IL-18 that have not been reported previously. Reduc-
tion of IL-18 reduced PMN influx at d 2 post instillation
but did not affect the resolution process. We have reported
essentially the same initial responses over d 2–4 to various
lots of LPS that were prepared at different times either
from P. aeruginosa [12] or from E. coli [15]. Therefore, this
highly reproducible model system is useful to elucidate
the mechanisms involved in the resolution process, to
identify which inflammatory mediators may enhance the
resolution of inflammation, and the elimination of hyper-
plastic epithelial cells along with the reversion of meta-
plastic mucous cells.
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